welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Jacques P. Tremblay, PhD
Department of Molecular Medicine
Faculty of Medicine, Université Laval
2705, Boulevard Laurier
Dr. Tremblay’s laboratory is renowned for his work on the transplantation of normal allogeneic myoblasts as a treatment for DMD. His Phase I clinical trial for this therapy showed that this transplant restores the expression of this protein in the patient’s muscle fibers.
In 2006, Dr. Tremblay received the Henry Friesen Award from the Royal College of Physicians and Surgeons of Canada for his work on the DMD therapy. His group is currently conducting a Phase I / II clinical trial on this therapy. In addition, his group is currently using CRISPR / Cas9 technology to correct the dystrophin gene, creating an additional deletion to produce a hybrid exon of the dystrophy gene, which not only restores the expression of dystrophin but also produces dystrophin with a normal structure.
Jacques P. Tremblay received a BSc in Biochemistry from McGill University in 1970, and a PhD in Neuroscience from UCSD (University of California in San Diego) in 1974. From 1975 to 1976, he was a postdoctoral fellow at the Laboratory of Neurobiology of l’Hôpital de l’Enfant-Jésus. Subsequently, he spent his entire career at Laval University.
CureDuchenne Ventures Commits $500,000 to 4D Molecular Therapeutics to Advance Next-Generation AAV Delivery of Gene ...CureDuchenne, a national venture phila...
Crispr Halted Muscular Dystrophy In Dogs. Someday, It Might Cure Humans.Today, our partner Dr. Eric Olson and hi...
U.S. appeals court upholds MIT, Harvard patents on CRISPR gene editingA U.S. appeals court on Monday allowed a...
AbCellera is enabling the translation of laboratory research to clinical application for fibrosis associated with co...Duchenne muscular dystrophy (DMD) is one...
Researchers Overcome Hurdle in CRISPR Gene Editing for Muscular DystrophyThe gene editing technique known as CRIS...
Bespoke Is Often Better: How Scientists Are Customizing Gene TherapyWhen it comes to products from suits to ...
Sarepta Announces Clinical Hold Lifted for its Duchenne Muscular Dystrophy Micro-dystrophin Gene Therapy ProgramSarepta Therapeutics, Inc., a commercial...